Bluebird Bio Inc (BLUE) 18.24 $BLUE
Ability Commerce Announces Alliance with JDA Software
PRWeb - Mon May 05, 6:01AM CDT
Ability Commerce, the leader in direct commerce retail systems, and JDA Software, Inc., the leading provider of supply chain and retail merchandising and planning solutions, are working together to provide increased value for the JDA(R) Direct Commerce Suite and JDA(R) Commerce Suite customer bases. Ability Commerce will provide professional services and consulting to JDA customers running the former Ecometry and Blue Martini systems. Services include, but are not limited to: Upgrades Server Migrations Data Conversions Credit Card Certifications Credit Card Tokenization Shipping Certifications System Health Checks Business Process Reviews
bluebird bio to Present at Three Upcoming Health Care Conferences
Business Wire - Thu May 01, 3:15PM CDT
bluebird bio, Inc. (Nasdaq: BLUE) announces that management will present at the Deutsche Bank 39th Annual Health Care Conference on Thursday, May 8, 2014 at 8:00 AM( EDT) at the InterContinental Boston Hotel, Boston, Massachusetts. Management will also present at the Bank of America Healthcare Conference on Wednesday, May 14, 2014 at 3:40 PM (PDT) at the Encore at Wynn Hotel, Las Vegas, Nevada and at the UBS Global Healthcare Conference on Wednesday, May 21, 2014 at 11:00 AM (ET) at the Sheraton New York Hotel, New York, New York.
Zacks Rank #5 Additions for Thursday - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Apr 10, 8:30AM CDT
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List for Thursday
What Falling Estimates & Price Mean for bluebird bio (BLUE) - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Apr 03, 7:43AM CDT
One such stock that you may want to consider dropping is bluebird bio which witnessed negative earnings estimate revisions in current quarter and current year.
Zacks Rank #5 Additions for Wednesday - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Apr 02, 8:30AM CDT
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List for Wednesday
bluebird bio Announces First Patient Transplanted in Phase 1/2 Northstar Study for the Treatment of Beta-Thalassemia
Business Wire - Thu Mar 27, 6:00AM CDT
bluebird bio, Inc. (Nasdaq:BLUE) a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic and orphan diseases, today announced that the first subject with beta-thalassemia major has been enrolled in its phase 1/2 Northstar Study (HGB-204) in the United States and has undergone infusion with bluebird bio's LentiGlobin drug product in an autologous hematopoietic stem cell transplantation.
Healthcare Companies Report Clinical Study Results, Financial Results and Stock Summaries - Analyst Notes on Endocyte, Ophthotech, AcelRx Pharmaceuticals, bluebird bio, and Cantel Medical
PR Newswire - Wed Mar 26, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Endocyte, Inc. (NASDAQ: ECYT), Ophthotech Corporation (NASDAQ: OPHT), AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX), bluebird bio, Inc. (NASDAQ: BLUE), and Cantel Medical Corp. (NYSE: CMN). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
'Mad Money' Lightning Round: VMware Is the One to Own
at The Street - Fri Mar 21, 5:00AM CDT
Cramer wants you to buy more Celgene at $140 and thinks Bluebird Bio is going higher.
Jim Cramer's 'Mad Money' Recap: Did You Panic Wednesday? Too Bad
at The Street - Thu Mar 20, 7:25PM CDT
You missed out on substantial gains, particularly in financials and technology, Cramer says.
bluebird bio Reports Fiscal Year End 2013 Financial Results
Business Wire - Wed Mar 05, 3:30PM CST
bluebird bio, Inc. (Nasdaq: BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic and orphan diseases, today reported financial results and operational highlights for the fiscal year ended December 31, 2013. At fiscal year end bluebird bio held $206.3 million in cash and cash equivalents.
New Appointments, Contract Extensions, Share Price Movements, Conference Schedules, and Closing of Public Offerings - Analyst Notes on Ariad, Novavax, Fonar, bluebird, and Cara
PR Newswire - Wed Mar 05, 6:24AM CST
Today, Analysts Review released its analysts' notes regarding Ariad Pharmaceuticals Inc. (NASDAQ: ARIA), Novavax, Inc. (NASDAQ: NVAX), Fonar Corp. (NASDAQ: FONR), bluebird bio, Inc. (NASDAQ: BLUE), and Cara Therapeutics Inc. (NASDAQ: CARA). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
bluebird bio (BLUE) Zooms: Stock Up 7.2% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Feb 28, 7:51AM CST
bluebird bio, Inc. (BLUE) was a big mover last session, as its shares surged over 7% on the day.
bluebird bio to Present at the Cowen and Company Health Care Conference
Business Wire - Wed Feb 26, 5:00PM CST
bluebird bio, Inc. (Nasdaq: BLUE) announces that management will present at the Cowen and Company 34th Annual Health Care Conference to be held March 2 - 5, 2014 at the Boston Marriott Copley Place Hotel, Boston, MA. Nick Leschly, Chief bluebird, will provide an overview of the company at the conference on Tuesday, March 4, 2014 at 8:00 AM (ET).
bluebird bio to Present at the Leerink Global Healthcare Conference
Business Wire - Wed Feb 05, 3:15PM CST
bluebird bio, Inc. (Nasdaq: BLUE) announces that management will present at the Leerink Global Healthcare Conference to be held February 12 - 13, 2014 at the Waldorf Astoria Hotel, New York, NY. Nick Leschly, Chief bluebird, will provide an overview of the company at the conference on Wednesday, February 12, 2014 at 8:25 AM (ET).
The State of Gene Therapy in a Biogen Idec World: Sangamo, Bluebird and Acceleron
at The Street - Thu Jan 23, 7:00AM CST
Sangamo benefits from a Biogen partnership, but what does it mean for rivals Bluebird and Acceleron?
2 Biotech Stocks Spiking on Unusual Volume
at The Street - Thu Jan 16, 6:00AM CST
Keep these biotech stocks trading on unusual volume on your radar.
J.P. Morgan Healthcare Confab Live Blog: Day Three
at The Street - Wed Jan 15, 9:12AM CST
TheStreet's Adam Feuerstein is providing live coverage of the most important healthcare investor conference of the year.
Conferences, Preliminary Revenues, Board Changes, Shareholders' Meeting Results, and Clinical Trial Initiation - Research Report on Antares, Quidel, bluebird bio, Given Imaging, and Immunomedics
PR Newswire - Tue Jan 14, 7:00AM CST
Today, Analysts' Corner announced new research reports highlighting Antares Pharma, Inc. (NASDAQ: ATRS), Quidel Corporation (NASDAQ: QDEL), bluebird bio, Inc. (NASDAQ: BLUE), Given Imaging Ltd. (NASDAQ: GIVN), and Immunomedics, Inc. (NASDAQ: IMMU). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
bluebird bio Appoints Dr James Mandell to its Board of Directors
Business Wire - Thu Jan 09, 5:29AM CST
bluebird bio, a clinical-stage biotechnology company focused on transforming the lives of patients with severe genetic and orphan diseases using gene therapy, announced today that James Mandell, M.D. has joined the company's board of directors. In addition, bluebird bio announced that Axel Polack, Ph.D., general partner at TVM Capital Partners, has stepped down from the board.
Ability Commerce Announces Alliance with JDA Software
PRWeb - Mon May 05, 6:01AM CDT
Ability Commerce, the leader in direct commerce retail systems, and JDA Software, Inc., the leading provider of supply chain and retail merchandising and planning solutions, are working together to provide increased value for the JDA(R) Direct Commerce Suite and JDA(R) Commerce Suite customer bases. Ability Commerce will provide professional services and consulting to JDA customers running the former Ecometry and Blue Martini systems. Services include, but are not limited to: Upgrades Server Migrations Data Conversions Credit Card Certifications Credit Card Tokenization Shipping Certifications System Health Checks Business Process Reviews
bluebird bio to Present at Three Upcoming Health Care Conferences
Business Wire - Thu May 01, 3:15PM CDT
bluebird bio, Inc. (Nasdaq: BLUE) announces that management will present at the Deutsche Bank 39th Annual Health Care Conference on Thursday, May 8, 2014 at 8:00 AM( EDT) at the InterContinental Boston Hotel, Boston, Massachusetts. Management will also present at the Bank of America Healthcare Conference on Wednesday, May 14, 2014 at 3:40 PM (PDT) at the Encore at Wynn Hotel, Las Vegas, Nevada and at the UBS Global Healthcare Conference on Wednesday, May 21, 2014 at 11:00 AM (ET) at the Sheraton New York Hotel, New York, New York.
Zacks Rank #5 Additions for Thursday - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Apr 10, 8:30AM CDT
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List for Thursday
What Falling Estimates & Price Mean for bluebird bio (BLUE) - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Apr 03, 7:43AM CDT
One such stock that you may want to consider dropping is bluebird bio which witnessed negative earnings estimate revisions in current quarter and current year.
Zacks Rank #5 Additions for Wednesday - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Apr 02, 8:30AM CDT
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List for Wednesday
bluebird bio Announces First Patient Transplanted in Phase 1/2 Northstar Study for the Treatment of Beta-Thalassemia
Business Wire - Thu Mar 27, 6:00AM CDT
bluebird bio, Inc. (Nasdaq:BLUE) a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic and orphan diseases, today announced that the first subject with beta-thalassemia major has been enrolled in its phase 1/2 Northstar Study (HGB-204) in the United States and has undergone infusion with bluebird bio's LentiGlobin drug product in an autologous hematopoietic stem cell transplantation.
Healthcare Companies Report Clinical Study Results, Financial Results and Stock Summaries - Analyst Notes on Endocyte, Ophthotech, AcelRx Pharmaceuticals, bluebird bio, and Cantel Medical
PR Newswire - Wed Mar 26, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Endocyte, Inc. (NASDAQ: ECYT), Ophthotech Corporation (NASDAQ: OPHT), AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX), bluebird bio, Inc. (NASDAQ: BLUE), and Cantel Medical Corp. (NYSE: CMN). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
'Mad Money' Lightning Round: VMware Is the One to Own
at The Street - Fri Mar 21, 5:00AM CDT
Cramer wants you to buy more Celgene at $140 and thinks Bluebird Bio is going higher.
Jim Cramer's 'Mad Money' Recap: Did You Panic Wednesday? Too Bad
at The Street - Thu Mar 20, 7:25PM CDT
You missed out on substantial gains, particularly in financials and technology, Cramer says.
bluebird bio Reports Fiscal Year End 2013 Financial Results
Business Wire - Wed Mar 05, 3:30PM CST
bluebird bio, Inc. (Nasdaq: BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic and orphan diseases, today reported financial results and operational highlights for the fiscal year ended December 31, 2013. At fiscal year end bluebird bio held $206.3 million in cash and cash equivalents.
New Appointments, Contract Extensions, Share Price Movements, Conference Schedules, and Closing of Public Offerings - Analyst Notes on Ariad, Novavax, Fonar, bluebird, and Cara
PR Newswire - Wed Mar 05, 6:24AM CST
Today, Analysts Review released its analysts' notes regarding Ariad Pharmaceuticals Inc. (NASDAQ: ARIA), Novavax, Inc. (NASDAQ: NVAX), Fonar Corp. (NASDAQ: FONR), bluebird bio, Inc. (NASDAQ: BLUE), and Cara Therapeutics Inc. (NASDAQ: CARA). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
bluebird bio (BLUE) Zooms: Stock Up 7.2% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Feb 28, 7:51AM CST
bluebird bio, Inc. (BLUE) was a big mover last session, as its shares surged over 7% on the day.
bluebird bio to Present at the Cowen and Company Health Care Conference
Business Wire - Wed Feb 26, 5:00PM CST
bluebird bio, Inc. (Nasdaq: BLUE) announces that management will present at the Cowen and Company 34th Annual Health Care Conference to be held March 2 - 5, 2014 at the Boston Marriott Copley Place Hotel, Boston, MA. Nick Leschly, Chief bluebird, will provide an overview of the company at the conference on Tuesday, March 4, 2014 at 8:00 AM (ET).
bluebird bio to Present at the Leerink Global Healthcare Conference
Business Wire - Wed Feb 05, 3:15PM CST
bluebird bio, Inc. (Nasdaq: BLUE) announces that management will present at the Leerink Global Healthcare Conference to be held February 12 - 13, 2014 at the Waldorf Astoria Hotel, New York, NY. Nick Leschly, Chief bluebird, will provide an overview of the company at the conference on Wednesday, February 12, 2014 at 8:25 AM (ET).
The State of Gene Therapy in a Biogen Idec World: Sangamo, Bluebird and Acceleron
at The Street - Thu Jan 23, 7:00AM CST
Sangamo benefits from a Biogen partnership, but what does it mean for rivals Bluebird and Acceleron?
2 Biotech Stocks Spiking on Unusual Volume
at The Street - Thu Jan 16, 6:00AM CST
Keep these biotech stocks trading on unusual volume on your radar.
J.P. Morgan Healthcare Confab Live Blog: Day Three
at The Street - Wed Jan 15, 9:12AM CST
TheStreet's Adam Feuerstein is providing live coverage of the most important healthcare investor conference of the year.
Conferences, Preliminary Revenues, Board Changes, Shareholders' Meeting Results, and Clinical Trial Initiation - Research Report on Antares, Quidel, bluebird bio, Given Imaging, and Immunomedics
PR Newswire - Tue Jan 14, 7:00AM CST
Today, Analysts' Corner announced new research reports highlighting Antares Pharma, Inc. (NASDAQ: ATRS), Quidel Corporation (NASDAQ: QDEL), bluebird bio, Inc. (NASDAQ: BLUE), Given Imaging Ltd. (NASDAQ: GIVN), and Immunomedics, Inc. (NASDAQ: IMMU). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
bluebird bio Appoints Dr James Mandell to its Board of Directors
Business Wire - Thu Jan 09, 5:29AM CST
bluebird bio, a clinical-stage biotechnology company focused on transforming the lives of patients with severe genetic and orphan diseases using gene therapy, announced today that James Mandell, M.D. has joined the company's board of directors. In addition, bluebird bio announced that Axel Polack, Ph.D., general partner at TVM Capital Partners, has stepped down from the board.
